However, in response, breast cancer cells increased the expression of Nrf2 (nuclear factor (erythroid-2 related) factor 2), which activated ARE and increased transcription of genes related with anti-oxidation and multidrug resistance transporters, enhancing survival from tamoxifen-induced oxidative damage [16, 45]. Here, NFE2L2 is linked to breast carcinoma.